CP-481,715 Nickel Allergy Study.

Phase 1

Completed

• Conditions: Dermatitis, Allergic Contact

• Registration Number: NCT00141180
• Lead Sponsor: Pfizer

Brief Summary

To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-09
• Study First Submitted: 2005-08-30
• Study First Submitted QC: 2005-08-30
• Study First Posted: 2005-09-01
• Study Completion: 2005-10
• Status Verified: 2005-11
• Last Update Submitted: 2006-07-23
• Last Update Posted: 2006-07-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

• A history of nickel allergy confirmed by a visual positive reaction (graded at least ++) to T.R.U.E. TEST.

Exclusion Criteria

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding contact allergic dermatitis or untreated, asymptomatic, seasonal allergies at time of dosing).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Effect of CP-481,715 on clinical response and cell infiltration after nickel challenge

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇩🇰 Hellerup, Denmark